放射学同步门肝静脉栓塞(RASPE)与大范围肝切除术前门静脉栓塞的比较
该回顾性研究比较了RASPE与PVE促进未来肝残余(FLR)生长的可行性、安全性和有效性。2016至2018年共纳入73例患者,RASPE组为FLR/TLV<25%者,PVE组为FLR/TLV<30%者,两组按年龄、性别、肿瘤类型和化疗次数匹配。结果显示RASPE组FLR增长更显著,且术后肝衰竭发生更少。
要点
- RASPE术后4周FLR体积增长61.18%,显著高于PVE的28.98%。
- RASPE组无术后肝衰竭,PVE组有7例发生(P=0.012)。
- RASPE可视为放射学版ALPPS,能安全诱导FLR显著增生。
核心结论
- RASPE可安全诱导FLR显著生长,且比PVE更有效,允许扩大肝切除并降低术后肝衰竭风险。
研究设计与样本
- 回顾性研究,2016至2018年纳入73例患者,RASPE组为FLR/TLV<25%者,PVE组为FLR/TLV<30%者,两组按年龄、性别、肿瘤类型和化疗次数匹配。
主要发现
- 两组技术成功率均为100%,栓塞后并发症发生率和栓塞至手术时间相似。
- PVE组栓塞前FLR/TLV为31.03%(范围18.33%-38.95%),RASPE组为22.91%(范围16.55%-32.15%),P<0.0001。
- 术后4周PVE组肝体积增加28.98%(范围9.31%-61.23%),RASPE组增加61.18%(范围23.18%-201.56%),P<0.0001。
- PVE组7例发生术后肝衰竭,RASPE组无发生(P=0.012)。
临床怎么用
- 对于FLR/TLV<25%需大范围肝切除的患者,可考虑RASPE以促进FLR生长并降低术后肝衰竭风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this retrospective study was to compare portal vein embolization (PVE) and radiologica simultaneous portohepatic vein embolization (RASPE) for future liver remnant (FLR) growth in terms of feasibility, safety, and efficacy. SUMMARY OF BACKGROUND DATA: After portal vein embolization (PVE), 15% of patients remain ineligible for hepatic resection due to insufficient hypertrophy of the FLR. RASPE has been proposed to induce FLR growth. MATERIALS AND METHODS: Between 2016 and 2018, 73 patients were included in the study. RASPE was proposed for patients with a ratio of FLR to total liver volume (FLR/TLV) of <25% (RASPE group). This group was compared to patients who underwent PVE for a FLR/TLV <30% (PVE group). Patients in the 2 groups were matched for age, sex, type of tumor, and number of chemotherapy treatments. FLR was assessed by computed tomography before and 4 weeks after the procedure. RESULTS: The technical success rate in both groups was 100%. Morbidity post-embolization, and the time between embolization and surgery were similar between the groups. In the PVE group, the FLR/TLV ratio before embolization was 31.03% (range: 18.33%-38.95%) versus 22.91% (range: 16.55-32.15) in the RASPE group (P < 0.0001). Four weeks after the procedure, the liver volume increased by 28.98% (range: 9.31%-61.23%) in the PVE group and by 61.18% (range: 23.18%-201.56%) in the RASPE group (P < 0.0001). Seven patients in the PVE group, but none in the RASPE group, had postoperative liver failure (P = 0.012). CONCLUSIONS: RASPE can be considered as "radiological associating liver partition and portal vein ligation for staged hepatectomy." RASPE induced safe and profound growth of the FLR and was more efficient than PVE. RASPE also allowed for extended hepatectomy with less risk of post-operative liver failure.
引用
- Laurent C, Fernandez B, Marichez A, et al. Radiological Simultaneous Portohepatic Vein Embolization (RASPE) Before Major Hepatectomy: A Better Way to Optimize Liver Hypertrophy Compared to Portal Vein Embolization. Ann Surg. 2020. PMID: 32675481. doi:10.1097/SLA.0000000000003905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。